Health ยท Pan-African
Gavi Urges Early Preparation for New TB Vaccines Expected From 2029
By: Ola Badawy
Gavi says next-generation tuberculosis vaccines could become available from 2029 and save 7.3 million lives between 2030 and 2050. The vaccine alliance is urging governments and partners, particularly in high-burden African countries, to plan for demand, manufacturing, financing and delivery before approvals.
Gavi, the Vaccine Alliance, is urging governments and health partners to begin preparing now for a new generation of tuberculosis vaccines that could become available from 2029.
TB causes around 1.2 million deaths a year, roughly one every 26 seconds, and Africa records the highest rates of cases and deaths of any region. For more than a century, the BCG vaccine has been the only licensed vaccine against the disease. Gavi says it protects infants and young children against severe forms of TB but has limited effect on pulmonary TB in adolescents and adults, who account for most transmission.
Gavi estimates that the new vaccines, if proven safe and effective, could save 7.3 million lives between 2030 and 2050. Its Early Market Shaping Roadmap for Novel TB Vaccines projects global demand averaging 86 million vaccination courses a year, and Gavi analysis suggests economic benefits of up to US$135 billion for low- and middle-income countries.
Emily Kobayashi, Gavi's Director of Vaccine Programmes, said the impact will depend on the characteristics of the approved vaccines and how quickly countries can introduce them. She identified uncertainty over future demand as a key risk, saying manufacturers need confidence that demand will exist before licensing to justify investing in production capacity.
Between now and 2029, she said, candidates must complete clinical trials while governments, manufacturers and partners assess demand, plan delivery, estimate manufacturing needs, develop policy recommendations and secure financing. She pointed to the malaria vaccine rollout, where preparations ran alongside trials, as an example of fast scale-up.
For African countries, preparation involves deciding how vaccines would fit into existing immunisation and TB programmes, which groups to prioritise and what resources are needed. Kobayashi also said preventing TB could help limit the spread of drug-resistant forms of the disease.